Anticoagulation control in patients with atrial fibrillation (AF) has a multidisciplinary approach although is usually managed by general practitioners (GP) or haematologists. The aim of our study was to assess the quality of anticoagulation control with vitamin K antagonists (VKAs) in relation to the responsible specialist in a "real-world" AF population. We consecutively enrolled VKA anticoagulated patients included in the FANTASIIA Registry from 2013 to 2015. We analysed demographical, clinical characteristics and the quality of anticoagulation control according to the specialist responsible (ie GPs or haematologists). Data on 1584 patients were included (42.5% females, mean age 74.0 ± 9.4 years): 977 (61.7%) patients were controlled by ...
IntroductionEfficacy and safety of vitamin K antagonists (VKAs) among atrial fibrillation (AF) patie...
Aims Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend ...
Aims Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend ...
Background: Anticoagulation control in patients with atrial fibrillation (AF) has a multidisciplina...
Original article[Abstract] Background. Anticoagulation control in patients with atrial fibrillation...
The efficacy and safety of oral anticoagulation (OAC) using the vitamin K antagonists (VKA) are clos...
The Atrial Fibrillation Better Care (ABC) pathway was proposed for a more integrated atrial fibrilla...
Introduction: The risk of stroke in atrial fibrillation (AF) can be significantly reduced by appropr...
Background: Atrial fibrillation (AF) is the most common chronic rhythm disorder. Patients with AF ar...
International audienceAIMS: This French study was set up to collect perceptions of general practitio...
Atrial fibrillation (AF) is associated with an increased risk of thromboembolic events. Many patient...
Background and objectives: Long-term therapy with oral anticoagulants is recommended for stroke prev...
Background and objectives: Long-term therapy with oral anticoagulants is recommended for stroke prev...
Aim. To study the frequency of prescribing anticoagulant therapy in outpatients with AF in accordanc...
Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend a tar...
IntroductionEfficacy and safety of vitamin K antagonists (VKAs) among atrial fibrillation (AF) patie...
Aims Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend ...
Aims Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend ...
Background: Anticoagulation control in patients with atrial fibrillation (AF) has a multidisciplina...
Original article[Abstract] Background. Anticoagulation control in patients with atrial fibrillation...
The efficacy and safety of oral anticoagulation (OAC) using the vitamin K antagonists (VKA) are clos...
The Atrial Fibrillation Better Care (ABC) pathway was proposed for a more integrated atrial fibrilla...
Introduction: The risk of stroke in atrial fibrillation (AF) can be significantly reduced by appropr...
Background: Atrial fibrillation (AF) is the most common chronic rhythm disorder. Patients with AF ar...
International audienceAIMS: This French study was set up to collect perceptions of general practitio...
Atrial fibrillation (AF) is associated with an increased risk of thromboembolic events. Many patient...
Background and objectives: Long-term therapy with oral anticoagulants is recommended for stroke prev...
Background and objectives: Long-term therapy with oral anticoagulants is recommended for stroke prev...
Aim. To study the frequency of prescribing anticoagulant therapy in outpatients with AF in accordanc...
Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend a tar...
IntroductionEfficacy and safety of vitamin K antagonists (VKAs) among atrial fibrillation (AF) patie...
Aims Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend ...
Aims Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend ...